Currently Approved Drug Could Boost Immunotherapy Against Liver Cancer
Researchers at University of Washington have discovered that a drug that is currently approved by the FDA could help in boosting the efficacy of immunotherapy against a rare type of liver cancer that has previously been unresponsive to checkpoint inhibitors. The preclinical study, whose findings appeared in the Gastroenterology journal, found that fibrolamellar carcinoma, an aggressive type of liver cancer, alters normal liver cells and causes them to produce the fibrous tissue that is characteristic of this type of cancer. T-cells that are meant to fight the cancer are then rechanneled into these fibrous bands and trapped there. As a result of this entrapment, the body’s immune…
